Whereas, abnormalities in AHN have been extensively investigated in AD mouse models based on APP or PSEN1/2 familial AD mutations (13, 14), the impact of tau pathology on AHN remains largely unclear in AD and other tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.